The World's Most Dangerous Swing Trader
The World's Most Dangerous Swing Trader
 |
Centene posted a GAAP loss for 2025 but management’s 2026 adjusted EPS guidance and recent technical signals point to a stabilization phase with upside potential in the near term. |
 |
Franklin Electric presents a mixed near-term picture: operational cash strength and a dividend increase underpin fundamental resilience, while directional technicals signal short-term consolidation ahead of catalyst-driven moves. |
 |
Strong liquidity and intensified field programs set the company into a clear preparatory phase for partnership and spin‑out milestones in early 2026. |
 |
Natural Grocers shows a mix of fading momentum and solid cash generation that supports a near-term corrective rebound; fundamentals signal operating leverage while technicals warn of waning upside momentum. |
 |
Telesat’s pivot toward its Lightspeed low‑Earth‑orbit program shows growing contract activity while legacy revenue contracts shrink; capital structure and operating losses keep valuation elevated. The next weeks should emphasize execution and financing clarity rather than revenue expansion. |
Brookfield Business Corporation moves into a corporate simplification phase while near-term technical signals suggest constrained upside and heightened sensitivity to momentum shifts.
 |
Tower Semiconductor shows a tactical pivot toward silicon photonics and AI infrastructure partnerships, positioning near-term operational cadence around photonics revenue ramps and strategic collaborations. |
 |
Aeva enters a period of tangible commercialization momentum, with new product launches and defense program awards sharpening near-term demand prospects. Operational metrics and valuation, however, continue to signal material execution and profitability challenges. |
 |
AngloGold Ashanti shows mixed momentum: short-term indicators point lower while longer-term averages and WMDST’s fair valuation suggest underlying support. Technical weakness near short-term resistance warrants caution for the coming weeks. |
 |
Mesa Laboratories shows fundamental cash-generation and a notable EPS beat while technical momentum softens; near-term price action should resolve the conflicting signals. The balance of stronger cash flow metrics against elevated leverage frames the immediate outlook. |